Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10045810HBVENSG00000111424.12protein_codingVDRNoNo7421P11473
TVIS30006137HIVENSG00000111424.12protein_codingVDRNoNo7421P11473
TVIS30019074HIVENSG00000111424.12protein_codingVDRNoNo7421P11473
TVIS30077286HIVENSG00000111424.12protein_codingVDRNoNo7421P11473
TVIS30079341HIVENSG00000111424.12protein_codingVDRNoNo7421P11473
TVIS20045047HPVENSG00000111424.12protein_codingVDRNoNo7421P11473
TVIS44017496HTLV-1ENSG00000111424.12protein_codingVDRNoNo7421P11473
TCGA Plot Options
Drug Information
GeneVDR
DrugBank IDDB00910
Drug NameParicalcitol
Target IDBE0000779
UniProt IDP11473
Regulation Typeagonist
PubMed IDs17139284; 17016423; 16076355; 19494617; 20204178; 11752352
CitationsOverington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Andress DL: Vitamin D treatment in chronic kidney disease. Semin Dial. 2005 Jul-Aug;18(4):315-21.@@Brancaccio D, Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M: New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. Contrib Nephrol. 2009;163:219-26. doi: 10.1159/000223802. Epub 2009 Jun 3.@@Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol. 2010;2010:621687. doi: 10.1155/2010/621687. Epub 2010 Mar 2.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
GroupsApproved; Investigational
Direct ClassificationVitamin D and derivatives
SMILES[H][C@@]1(CC[C@@]2([H])C(CCC[C@]12C)=CC=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)C=C[C@H](C)C(C)(C)O
Pathways
PharmGKBPA450798
ChEMBLCHEMBL1200622